Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1977 Dec;21:225–230. doi: 10.1289/ehp.7721225

Metabolism and toxicity of 2,2,2-trifluoroethyl vinyl ether.

V Fiserova-Bergerova
PMCID: PMC1475355  PMID: 25763

Abstract

A review on metabolism and toxicity of the fluorinated anesthetic agent, fluroxene, is presented. Fluroxene anesthesia is nontoxic to man but fatal to many experimental animals. The fluroxene molecule (2,2,2-trifluroethyl vinyl ether) is composed of two moieties; both are toxic as a result of their metabolism: the vinyl moiety destroys heme of cytochrome P-450 while being metabolized to the final product, CO2. The trifluoroethyl moiety is oxidized to trifluoroethanol (TFE) and trifluoroacetic acid (TFAA), and the acute toxicity of fluroxene is related to this pathway. The ratio of metabolities (TFAA to TFE) excreted by different species exposed to fluroxene varies; whenever highly toxic TFE is the major metabolite, fluroxene toxicity is high (rodents, dogs, phenobarbital pretreated monkeys), whenever TFAA is the major metabolite (man, monkey) fluroxene is not toxic. Toxicity in different species also correlates with the extent of glutathione depletion following fluroxene exposure. Fluroxene metabolism and toxicity are modified by drugs metabolized by or affecting the activity of the microsomal cytochrome P-450-system or enzymes involved in ethanol metabolism. The susceptibility of fluroxene to two enzymatic systems which are modified by environmental and genetic factors may explain the large differences in fluroxene toxicity to various species. The fate of one-third of fluroxene administered to man remains unknown.

Full text

PDF
225

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Airaksinen M. M., Rosenberg P. H., Tammisto T. A possible mechanism of toxicity of trifluoroethanol and other halothane metabolites. Acta Pharmacol Toxicol (Copenh) 1970;28(4):299–304. doi: 10.1111/j.1600-0773.1970.tb00556.x. [DOI] [PubMed] [Google Scholar]
  2. Airaksinen M. M., Tammisto T. Toxic actions of the metabolites of halothane: LD 50 and some metabolic effects of trifluoroethanol and trifluoroacetic acid in mice and guinea pigs. Ann Med Exp Biol Fenn. 1968;46(2):242–248. [PubMed] [Google Scholar]
  3. Bagwell E. E., Gadsden R. H., Risinger K. B., Woods E. F. Blood levels and cardiovascular dynamics during fluroxene anaesthesia in dogs. Can Anaesth Soc J. 1966 Jul;13(4):378–389. doi: 10.1007/BF03002180. [DOI] [PubMed] [Google Scholar]
  4. Blake D. A., Cascorbi H. F. A note on the biotransformation of fluroxene in two volunteers. Anesthesiology. 1970 Jun;32(6):560–560. doi: 10.1097/00000542-197006000-00021. [DOI] [PubMed] [Google Scholar]
  5. Blake D. A., Cascorbi H. F., Rozman R. S., Meyer F. J. Animal toxicity of 2,2,2-trifluoroethanol. Toxicol Appl Pharmacol. 1969 Jul;15(1):83–91. doi: 10.1016/0041-008x(69)90135-5. [DOI] [PubMed] [Google Scholar]
  6. Blake D. A., Rozman R. S., Cascorbi H. F., Krantz J. C., Jr Anesthesia. LXXIV. Biotransformation of fluroxene. I. Metabolism in mice and dogs in vivo. Biochem Pharmacol. 1967 Jul 7;16(7):1237–1248. doi: 10.1016/0006-2952(67)90155-4. [DOI] [PubMed] [Google Scholar]
  7. Cascorbi H. F., Singh-Amaranath A. V. Fluroxene toxicity in mice. Anesthesiology. 1972 Nov;37(5):480–482. doi: 10.1097/00000542-197211000-00002. [DOI] [PubMed] [Google Scholar]
  8. Cascorbi H. F., Singh-Amaranath A. V. Modification of fluroxene toxicity. Anesthesiology. 1973 May;38(5):454–457. doi: 10.1097/00000542-197305000-00007. [DOI] [PubMed] [Google Scholar]
  9. Gion H., Yoshimura N., Holaday D. A., Fiserova-Bergerova V., Chase R. E. Biotransformation of fluroxene in man. Anesthesiology. 1974 Jun;40(6):553–562. doi: 10.1097/00000542-197406000-00008. [DOI] [PubMed] [Google Scholar]
  10. Harris J. A., Cromwell T. H. Jaundice following fluroxene anesthesia. Anesthesiology. 1972 Oct;37(4):462–463. doi: 10.1097/00000542-197210000-00022. [DOI] [PubMed] [Google Scholar]
  11. Harrison G. G., Smith J. S. Massive lethal hepatic necrosis in rats anesthetized with fluroxene, after microsomal enzyme induction. Anesthesiology. 1973 Dec;39(6):619–625. doi: 10.1097/00000542-197312000-00012. [DOI] [PubMed] [Google Scholar]
  12. Ivanetich K. M., Bradshaw J. J., Marsh J. A., Harrison G. G., Kaminsky L. S. The role of cytochrome P-450 in the toxicity of fluroxene (2,2,2-trifluoroethyl vinyl ether) anaesthesia in vivo. Biochem Pharmacol. 1976 Apr 1;25(7):773–778. doi: 10.1016/0006-2952(76)90145-3. [DOI] [PubMed] [Google Scholar]
  13. Ivanetich K. M., Bradshaw J. J., Marsh J. A., Kaminsky L. S. The interaction of hepatic microsomal cytochrome P-450 with fluroxene (2,2,2-trifluoroethyl vinyl ether) in vitro. Biochem Pharmacol. 1976 Apr 1;25(7):779–784. doi: 10.1016/0006-2952(76)90146-5. [DOI] [PubMed] [Google Scholar]
  14. Ivanetich K. M., Marsh J. A., Bradshaw J. J., Kaminsky L. S. Fluroxene (2,2,2-trifluoroethyl vinyl ether) mediated destruction of cytochrome P-450 in vitro. Biochem Pharmacol. 1975 Nov 1;24(21):1933–1936. doi: 10.1016/0006-2952(75)90377-9. [DOI] [PubMed] [Google Scholar]
  15. Johnston R. R., Cromwell T. H., Eger E. I., 2nd, Cullen D., Stevens W. C., Joas T. The toxicity of fluroxene in animals and man. Anesthesiology. 1973 Apr;38(4):313–319. doi: 10.1097/00000542-197304000-00003. [DOI] [PubMed] [Google Scholar]
  16. Johnston R. R., Eger E. I., 2nd, Stevens W. C., White P. F. Fluroxene toxicity in dogs: possible mechanisms. Anesth Analg. 1974 Nov-Dec;53(6):998–1003. doi: 10.1213/00000539-197453060-00035. [DOI] [PubMed] [Google Scholar]
  17. KRANTZ J. C., Jr, CARR C. J., LU G., BELL F. K. Anesthesia. XL. The anesthetic action of trifluoroethyl vinyl ether. J Pharmacol Exp Ther. 1953 Aug;108(4):488–495. [PubMed] [Google Scholar]
  18. Munson E. S., Malagodi M. H., Shields R. P., Tham M. K., Fiserova-Bergerova V., Holaday D. A., Perry J. C., Embro W. J. Fluroxene toxicity induced by phenobarbital. Clin Pharmacol Ther. 1975 Dec;18(6):687–699. doi: 10.1002/cpt1975186687. [DOI] [PubMed] [Google Scholar]
  19. Rosenberg P. H. Decrease in reduced glutathione and NADPH and inhibition of glucose-6-phosphate dehydrogenase activity caused by metabolites of fluroxene and halothane. Ann Med Exp Biol Fenn. 1971;49(2):84–88. [PubMed] [Google Scholar]
  20. Rosenberg P. H., Wahlström T. Trifluoroacetic acid and some possible intermediate metabolites of halothane as haptens. Anesthesiology. 1973 Mar;38(3):224–227. doi: 10.1097/00000542-197303000-00004. [DOI] [PubMed] [Google Scholar]
  21. Tucker W. K., Munson E. S., Holaday D. A., Fiserova-Bergerova V., Turner B. M. Hepatorenal toxicity following fluroxene anesthesia. Anesthesiology. 1973 Jul;39(1):104–107. doi: 10.1097/00000542-197307000-00014. [DOI] [PubMed] [Google Scholar]
  22. VANDYKE R. A., CHENOWETH M. B. METABOLISM OF VOLATILE ANESTHETICS. Anesthesiology. 1965 May-Jun;26:348–357. doi: 10.1097/00000542-196505000-00013. [DOI] [PubMed] [Google Scholar]
  23. Van Dyke R. A., Wood C. L. In vitro studies on irreversible binding of halothane metabolite to microsomes. Drug Metab Dispos. 1975 Jan-Feb;3(1):51–57. [PubMed] [Google Scholar]
  24. Wollman S. B., Surks S. N. Case history number 75: hepatic damage after fluroxene anesthesia. Anesth Analg. 1973 Nov-Dec;52(6):942–945. [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES